Ask AI

Addressing Challenges and Implementing Care Strategies to Optimize BCMA Bispecific Antibody Therapy in RRMM: Expert Insights, Patient Resources, and Adaptive Decision Support

Enhance your understanding of BCMA bispecific antibodies currently used to manage relapsed/refractory multiple myeloma to optimize therapy and improve adherence through an interactive decision support tool, certified interactive case challenge and on-demand webcast, expert-written ClinicalThought commentary, podcast, downloadable resources, and downloadable slides.

Share

Program Content

Activities

MM BsAb Patient Resource
What I Wish I’d Known Before Starting Bispecific Antibody Therapy for Multiple Myeloma: A Patient Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: November 20, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC. in partnership with Smart Patients.

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Partners

Smart Patients

ProCE Banner